Analytical and Chemical Enhancements to Improve Efficacy and Accuracy of Therapeutic Oligonucleotides
See how top pharma players are addressing impure, unstable, and off-target oligos
Boosting the Efficacy of Safe, Scalable, & Precise Vaccines
Innovations in mRNA Technology, RNA Therapeutics, and Cancer Immunotherapy for 2024
.png)
Tumbler: A Highly Customizable Antibody Optimization Suite
On-demand presentation, presented by Michali Izhaky, Bioinformatics Scientist at Charles River
Leading Innovations in Fab, ScFv, & VHH Production and Engineering
On-demand webinar presented by Dr Jiansheng Wu, Head of Protein Sciences and Vice President at WuXi Biologics
Advancing Immunotherapy: The Critical Role of GMP-Grade Cytokines in Cell Therapy
On-demand webinar presented by Ritwika Biswas, Field Application Scientist at Sino Biological
Optimizing Bispecific Antibody Production: From Identifying Optimal Pairings to Scale-up Processes
On-demand webinar presented by Dr Jiansheng Wu, Head of Protein Sciences and Vice President at WuXi Biologics
Unlocking the Future of Immune Cancer Therapy
A concise report featuring insights from the prominent though leaders of Immuno 2024.
Antibody & Protein Engineering
AstraZeneca Suffers Sales Decline for COVID Med Evusheld
A 24 million loss has been reported for the preventative COVID-19 treatment.
Antibody & Protein Engineering
Market Battle for Rare Disease Treatment
Argenx and AstraZeneca are set to become market rivals in their general myasthenia gravis (gMG) treatments, analysts claim.
Immuno-Oncology
AAV Gene Therapy and CAR T Therapies: Immunogenicity and Immunoassay Development
Dr. Vibha Jawa, Executive Director, Nonclinical Disposition and Bioanalysis at BMS
Gene Therapy Development
Abundant Stochastic Off-Target Activity by Base Editors
Can complementary approaches for off-target quantification demonstrate substantial levels in various state-of-the-art editors?
NextGen Therapeutics
Bispecific Antibodies for Solid Tumours
Laura von Schantz, Vice President of Discovery at Alligator Bioscience, leads a discussion on the current and future opportunities of bispecific antibodies for solid tumour treatment.
European Approval for Monkeypox Vaccine
The European Commission (EC) has approved Bavarian Nordic’s Imvanex vaccine which protects against monkeypox, and diseases caused by the vaccinia virus.
Gene Therapy Development
When to Cut and When to Inhibit? A Low-Throughput, Hands-On Investigation Of CRISPR-Cut and CRISPRi Efficiencies In iPSC And Neural Cells
Gene knockdown – the manual reduction of a particular gene's expression in target cells – entails the modification of cellular development in young cells. CRISPR gene editing techniques enable researchers such as Pia Johansson to induce gene knockdown in target cells.
Gene Therapy Development
Overcoming the Challenges of Precision Genome Editing
Experts from academia and industry discuss the current obstacles and opportunities for genome editing during a roundtable session at Gene Therapy Development & Manufacturing: In-Person.
3D Cell Culture
Speaker Insights – In Conversation with Pedro-Caetano Pinto
Discover key insights into the application of microphysiological systems for advanced kidney and prostate cancer research.
Antibody & Protein Engineering
Widening the Therapeutic Window: Development of Antibody Drug Conjugates for Solid Tumours
Compared to non-solid tumours, solid tumours are more difficult to treat with conventional therapeutic methods. Antibody drug conjugates – biopharmaceutical drugs designed as a targeted therapy for treating cancer – represent a viable treatment alternative.
Antibody & Protein Engineering
Novartis Withdraws Tislelizumab Submission
Novartis scraps US submission of tislelizumab as a monotherapy for non-small cell lung cancer.